Description du projet
Une nouvelle solution permet de soulager les personnes souffrant de bronchopneumopathie chronique
Le projet STOP-COPD, financé par l’UE, a mis au point un nouveau dispositif, appelé PulseHaler™, afin de traiter la bronchopneumopathie chronique obstructive (BPCO), une maladie évolutive touchant les poumons. Le dispositif parvient à ouvrir les petites voies respiratoires, qui s’effondrent chez les patients atteints de BPCO, ce qui rend leur respiration difficile. PulseHaler™ améliore la capacité à faire de l’exercice physique, réduit l’essoufflement et améliore la qualité de vie des personnes souffrant de BPCO. Les chercheurs entendent optimiser le dispositif avec de nouvelles caractéristiques et fonctionnalités et le préparer pour une fabrication à grande échelle. Les patients atteints de BPCO se comptant en millions rien qu’en Europe, le dispositif est susceptible de réduire considérablement les coûts de soins de santé associés.
Objectif
Chronic Obstructive Pulmonary Disease (COPD) is a progressive, debilitating, disease of the lungs which affects 50M Europeans and kills 160,000 every year, with an annual cost burden of €141B. Respinova Ltd. has invented a novel device, called PulseHaler™, to treat COPD in a revolutionary way by opening the small airways, which are known to collapse in COPD patients thereby making it increasingly difficult to breathe. No other COPD treatment in the market today can effectively open the small airways. In a clinical trial, the PulseHaler™ was shown to substantially improve the functional capabilities and quality of life of COPD sufferers. If PulseHaler™ can reduce costs by the same magnitude to which it has been demonstrated to improve patient’s exercise capacity (the strongest predictor of morbidity and mortality), the current cost burden of COPD in Europe could be reduced by up to €21B annually.
After winning a SMEi-1 grant and receiving a Seal of Excellence certificate for our first SMEi-2 application, we intend to complete several actions which will bring the PulseHaler™ to the commercial market in this SMEi-2 project. The design of the device will be finalized incorporating features and functions identified in our successful SMEi-1 project. We will then prepare the PulseHaler™ for large scale manufacturing. We will test the PulseHaler™ in a clinical study of COPD patients across several sites, to gather additional efficacy and usability data identified by KOLs in SMEi-1 as important to support uptake of the product in the market. We will continue to develop our reimbursement strategy for initial markets, finalize distribution arrangements in those markets, obtain regulatory approval, and proceed to launch the PulseHaler™.
Respinova Ltd. is a 10 year old SME based in Israel with 7 employees. We have a seasoned management team with decades of combined medical device, business and leadership experience.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
4672408 Herzliya Pituach
Israël
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.